[PROSPECTIVES FOR THE USE OF MONOAMINE OXIDASE INHIBITORS IN PEDIATRICS].
D001168:Arthritis; D001172:Arthritis, Rheumatoid; D002648:Child; D004295:Dihydroxyphenylalanine; D004837:Epinephrine; D007223:Infant; D007490:Iproniazid; D008137:Longitudinal Studies; D008996:Monoamine Oxidase Inhibitors; D009638:Norepinephrine; D010372:Pediatrics; D010600:Pharmacology; D011446:Prospective Studies; D014363:Tryptamines; D014364:Tryptophan
D008996:Monoamine Oxidase Inhibitors; D014363:Tryptamines; D004295:Dihydroxyphenylalanine; D014364:Tryptophan; D007490:Iproniazid; C038034:etryptamine; D009638:Norepinephrine; D004837:Epinephrine
ARTHRITIS, RHEUMATOID; CHILD; DOPA; EPINEPHRINE; ETRYPTAMINE; INFANT; IPRONIAZID; MONOAMINE OXIDASE INHIBITORS; NOREPINEPHRINE; PEDIATRICS; PHARMACOLOGY; REVIEW; TRYPTOPHAN
PROSPETTIVE PER L'IMPIEGO IN PEDIATRIA DEGLI INIBITORI DELLA MONOAMINOSSIDASI.